Clinical Trial

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-13; most recent amendment 2026-05-29.
Trial Details
NCT Number NCT07217184
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 30 participants
Start Date 2021-07-29
Primary Completion 2025-04-17 (estimated)
Study Completion 2027-03-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-25